Our Take
ADCs are real oncology progress, but the commercial bottleneck isn't chemistry—it's the unglamorous work of packaging small batches of hazardous biologics across multiple geographies, fast.
Why it matters
ADC approvals are accelerating (93 Phase III trials in 2025 vs. 31 in 2023), and the market is forecast to triple to $60 billion by 2030. Pharma companies launching these therapies face a hard constraint: contract packaging partners who can handle both the dual toxicity profile of the drug and the operational chaos of indication expansion, label changes, and global SKU proliferation without slowing time-to-market.
Do this week
Clinical operations and supply chain leads: audit your current packaging partner's high-containment facility certifications and multi-country cold-chain capabilities before your ADC enters Phase III, so you avoid launch delays when indications expand.
ADC market expands rapidly, complexity moves downstream
As of May 2026, 23 antibody-drug conjugates have gained regulatory approval globally, with 412 distinct programs across clinical trials (per GlobalData). The market stood at $20 billion in 2025 and is forecast to reach $60 billion by 2030.
Phase III trial initiation for ADCs nearly tripled in two years: 31 trials in 2023, 67 in 2024, 93 in 2025. This acceleration reflects both the clinical efficacy of the class and the field's maturation past its original oncology scope into autoimmune disease, viral infection, and neurology research pipelines.
The commercial reality, however, differs from the lab story. ADCs pair a potent small-molecule payload with a monoclonal antibody targeting system. That dual chemistry demands specialized secondary packaging: light-protective cartons, lyophilized powder in sterile vials, and containment controls that protect both the biologically active component from temperature, humidity, and light degradation and the operator from hazardous material exposure.
Agility, not scale, is the actual constraint
Early-stage ADC launches typically serve narrow, indication-specific populations. Successful drugs then expand across multiple tumor types and earlier treatment lines, driving label changes, SKU proliferation, and batch-size volatility. A packaging partner optimized for high-volume, low-mix manufacturing becomes a liability.
According to Jeff Benedict, Chief Commercial Officer of Sharp (a contract packaging organization), "Many ADCs are launched with relatively small, indication-specific patient populations and then expand over time as new indications are approved. This demands a specialist 'high mix-low volume' packaging environment capable of supporting small batch production, frequent changeovers, and evolving label and configuration requirements."
Pharma companies increasingly outsource secondary packaging to contract development and manufacturing organizations (CDMOs) and contract packaging organizations (CPOs) that have already invested in the specialized containment systems, enhanced operator safety protocols, and rigorous environmental controls needed. The cost of mistake is high: any deviation in packaging or handling process risks significant implications for product and human safety.
Beyond operational flexibility, ADCs also require multi-country launch coordination. Pharma companies need packaging partners with US Foreign-Trade Zones, EU QP release capability, and cold-chain logistics networks that can certify batches and manage market release in parallel across regions without slowing commercial momentum.
Plan your packaging infrastructure now
If your ADC is in Phase II or early Phase III, begin systematic vendor evaluation of contract packaging partners. Audit their high-containment facilities for HVAC efficiency, real-time digital monitoring, and proven multi-country certification processes. Request case studies of previous indication expansions and label changes to assess their agility and compliance track record.
Early engagement also unlocks design collaboration. Packaging partners who engage during development help optimize product protection, sustainability (through operational efficiency and targeted material reduction), and compatibility with future delivery formats—pre-filled syringes, autoinjectors, pen platforms—that improve patient convenience but demand fresh packaging validation.
The ADC market's speed advantage goes to companies that treat packaging as a strategic control from IND forward, not a commodity problem at launch.